News

Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference

SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing…

1 year ago

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ERIN CARTER TO BOARD OF DIRECTORS

Rutherford, NJ, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company…

1 year ago

BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT™ in High-Risk Early-Stage Triple Negative Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”…

1 year ago

Pardes Biosciences Announces Closing of Tender Offer

CARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) (Pardes or the Company) today announced that…

1 year ago

Peak Bio, Inc., Announces Appointment of Michael Friedman to Board of Directors

Pleasanton, CA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a…

1 year ago

BioVie to Host Virtual KOL Event on NE3107 in Alzheimer’s Disease on September 7, 2023

CARSON CITY, Nev., Aug. 31, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company…

1 year ago

InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23

TEL AVIV, Israel, and MIAMI, Aug. 31, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic…

1 year ago

Boosh Enters Into US Licensing Agreement and Line of Credit

Vancouver, British Columbia--(Newsfile Corp. - August 31, 2023) - Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77i) ("Boosh" or the…

1 year ago

Progress Update on Securities

HALIFAX, NS / ACCESSWIRE / August 30, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) has completed, with its Transfer Agent,…

1 year ago

Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA(TM) (ACER-001) with Acer Therapeutics

Acer Therapeutics buys Relief Therapeutics' stake in OLPRUVA™ worldwide, excluding geographical Europe, providing an upfront payment of $10 million in…

1 year ago